Novartis Investigative Site

Lin-ko 33305

0 studies enrolling now · 7 studies all time

What they study most

Acute Decompensated Heart Failure, Advanced Neuroendocrine Tumors of Pancreatic Origin, Behcet Disease, Congestive Heart Failure, Hepatitis C, Non-Small Cell Lung Cancer, Partial Onset Seizures, Uveitis

Studies at this site

• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer — Stopped early
• Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures — Completed
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment — Completed
• 38 Week Extension Study to CAIN457C2303 — Stopped early
• Phase III Study in Refractory Behcet's Disease — Completed
• Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors — Completed
• Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure — Completed